Subconjunctival Nanoparticle Carboplatin in the Treatment of Murine Retinoblastoma

Open Access
Publisher Website
Google Scholar
Abstract
Retinoblastoma is the most common eye cancer in children, accounting for 11% of all infant cancers and 3% of cancers developing in children younger than 15 years. There are 300 new cases of retinoblastoma per year in the United States.1 For unilateral, sporadic cases, enucleation is the treatment of choice, whereas other treatment modalities are considered for the familial, bilateral cases.2,3 Radiation therapy and/or systemic chemotherapy with carboplatin, etoposide phosphate, and vincristine sulfate are preferred treatment options, which are associated with increased incidence of systemic adverse effects and secondary malignancies.4-8